NEWCARDIO INC.

29.07.2010 18:16 http://www.finanznachrichten.de/nachrichten-2010-07/17552774-newcardio-announces-new-dollar-1-5-million-line-of-credit-with-existing-shareholders-strengthens-company-s-position-for-strategic-relationships-and-008.htm NewCardio Announces New $1.5 Million Line of Credit with Existing Shareholders / Strengthens Company's Position for Strategic Relationships and Facilitates Ongoing Commercialization of QTinno SANTA CLARA, Calif., July 29 /PRNewswire-FirstCall/ -- NewCardio, Inc., (BULLETIN BOARD: NWCI) a cardiac diagnostic technology provider, today announced that it has entered into a new line of credit with three of its existing shareholders, one of which is represented on the Board of Directors, to strengthen its financial position. This will allow the company further time to fully commercialize its lead solution, QTinno(TM). In conjunction with signing this credit line, the company withdrew the S-1 registration statement, previously filed with the Securities and Exchange Commission (SEC) as it does not currently intend to pursue the public offering. Management believes that the company has sufficient operating capital to sustain its operations and fund its business plan at this time. The credit facility is part of a series of steps designed to improve the company's ability to identify and attract potential strategic relationships and/or investors, which is intended to enable the company to maximize the value to be derived through continued development of its 3D platform technology. ...(weiter siehe LINK)

02.06.2010 14:39 http://www.finanznachrichten.de/nachrichten-2010-06/17053967-newcardio-selected-to-make-presentations-at-15th-annual-world-congress-on-heart-disease-004.htm NewCardio Selected to Make Presentations at 15th Annual World Congress on Heart Disease Presentations Highlight the Company's Advances in Telemedicine NewCardio, Inc., (OTCBB: NWCI) a cardiac diagnostic technology provider, announced today that two of its most recent medical and technical submissions have been accepted for presentation at the prestigious 15th Annual World Congress on Heart Disease to be held in Vancouver BC on July 24-27, 2010. The Company will present data from both the advanced coronary artery disease (CAD) and atrial fibrillation (AF) clinical studies, with additional information from ongoing CardioBip™ clinical studies. The data supports CardioBip's suitability for long-term monitoring of patients with CAD and AF. The Company believes that acceptance of these submissions - which present important clinical data supporting the accuracy and effectiveness of its CardioBip product - reflects the growing interest in telemedicine and the recognition of NewCardio's technologies as effective solutions in the field. CardioBip is a unique, hand held device that gives accurate and timely diagnoses of acute cardiac events, and facilitates immediate intervention in life-threatening situations - even when the patient is far removed from a medical care center. Images of the CardioBip are available at www.newcardio.com/products-cardio-bip.php. Branislav Vajdic, Ph.D., NewCardio's CEO, commented, "Our acceptance to the 15th Annual World Congress on Heart Disease reflects the remarkable and ongoing success of our academic medical collaborators, and our technical and scientific teams. We believe that they will provide strong technical and clinical evidence supporting the potential of CardioBip as a key telemedicine solution for monitoring patients with very serious and unfortunately common cardiac diseases. CardioBip, without any leads and wires, is patient tolerable and provides reconstructed full 12-lead ECG data. Many cardiac patients would benefit from this improved diagnostic tool and its better long-term monitoring options." The Congress will provide the opportunity for a comprehensive overview of the latest research developments in cardiovascular medicine, primarily in the areas of molecular biology, coronary artery disease, heart failure, cardiac arrhythmias and cardiac surgery. ... (weiter siehe LINK!)

NewCardio to Perform First Revenue-Generating QT Study Using QTinno / NewCardio Now Has Master Services Agreements (MSAs) in Place with Three of the World's Leading CROs 29.04.2010 14:09 http://www.finanznachrichten.de/nachrichten-2010-04/16762771-newcardio-to-perform-first-revenue-generating-qt-study-using-qtinno-newcardio-now-has-master-services-agreements-msas-in-place-with-three-of-the-w-008.htm SANTA CLARA, Calif., April 29 /PRNewswire-FirstCall/ -- NewCardio, Inc., (BULLETIN BOARD: NWCI) a cardiac diagnostic technology provider, announced today that a leading global biopharmaceutical services provider has signed a MSA, licensing NewCardio's QTinno(TM) software solution to enhance its delivery of fully automated cardiac safety analyses for early phase QT studies. The CRO is expected to deploy QTinno in several clinical unit locations worldwide. In addition, the CRO has signed a services work order related to the first study using QTinno, which is scheduled to be initiated this June. "NewCardio now has agreements with three of the leading CROs in the industry," said Vincent Renz, NewCardio's President and Chief Operating Officer. "We are excited about the prospects of this latest agreement, which will result in initial study-related revenue for NewCardio. We continue to believe the transition from semi-automated to fully automated cardiac safety analysis in early phase QT studies is inevitable and accelerating, and the successful completion of our initial studies is expected to lead the market to shift to more high quality, cost effective fully automated studies in the near future. For the CRO, this agreement expands their scope of services in QT studies, enabling them to enhance delivery of high-quality cardiac safety analyses." NewCardio's innovative 3D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12-lead electrocardiogram (ECG). NewCardio's lead product is QTinno, a software suite that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators. The Company believes that its QTinno, software-based, analytical technology is the industry's first solution for the reliable automated analysis of ECGs used to determine cardiac toxicity during drug development. About NewCardio, Inc. NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit http://www.newcardio.com/. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements. To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0 Investor Contact: Hayden IR Jeff Stanlis, Partner (602) 476-1821 jeff@haydenir.com NewCardio, Inc. CONTACT: Investors, Jeff Stanlis, Partner of Hayden IR, +1-602-476-1821, jeff@haydenir.com, for NewCardio, Inc. Web Site: http://www.newcardio.com/ © 2010 PR Newswire

Clinilabs Signs MSA with NewCardio, Inc. for QTinno Date : 04/08/2010 @ 8:00AM Source : PR Newswire Stock : Newcardio (BB) (NWCI) http://ih.advfn.com/p.php?pid=nmona&cb=1270728608&article=42299034&symbol=NB%5ENWCI Master Services Agreement Enables Clinilabs to Add ECG Core Lab Services, Extending its Scope of Services and Capturing Additional Revenue PR Newswire NEW YORK, April 8 NEW YORK, April 8 /PRNewswire-FirstCall/ -- Clinilabs, a New York-based contract research organization that provides early phase and specialty clinical drug development services to the pharmaceutical industry, announced today that it has signed a Master Services Agreement (MSA) with NewCardio, Inc. (OTC Bulletin Board: NWCI), a cardiac diagnostic technology provider. Clinilabs has licensed NewCardio's QTinno™ software solution in order to perform fully-automated cardiac safety analyses in cardiac intensive and thorough QT studies. In addition, Clinilabs has signed a services work order, including standard operating procedures (SOP) and validation kits, as well as professional services, so NewCardio can assist Clinilabs in developing an ECG core laboratory. The Master Services Agreement enables Clinilabs to utilize QTinno to provide customers with advanced, accurate, and efficient fully-automated cardiac safety studies at its clinical research unit (CRU) in Manhattan. The relationship with NewCardio also will enable Clinilabs to compete in the market for ECG core laboratory services by providing the professional services needed to integrate ECG core lab functions into Clinilabs' existing core data center, which currently serves clinical trials in 33 countries. NewCardio is expected to recognize revenue from this relationship beginning in March 2010 with the installation and validation of its systems. Clinilabs is expected to recognize revenue as early as Q3 2010 from clinical trials conducted with the QTinno software solution. "This announcement is further evidence of the growing adoption of QTinno™ by innovative clinical trial service providers looking to deliver quality cardiac safety analysis with higher accuracy and lower intrinsic variability in a timely and cost-effective manner," said Vincent Renz, NewCardio's President and Chief Operating Officer. "Our target customers are clinical trial service providers looking to deploy our proven technology to expand services and grow market opportunities. For Clinilabs, adding to its available scope of services by utilizing QTinno accomplished these two important goals." Gary K. Zammit, PhD, President and CEO of Clinilabs, added, "NewCardio's QTinno, coupled with its team's history and expertise in delivering cardiac safety services to leading pharmaceutical companies, has given us an incredible opportunity to expand our service portfolio and deliver value to our clients. We can now provide a differentiated and low cost solution for ECG data analysis to an industry that has been seeking a meaningful alternative to existing methods for some time." Both NewCardio and Clinilabs will be present at the upcoming 19th Annual Partnerships in Clinical Trials conference to be held in Orlando, FL April 12-14th. NewCardio will be at booth # 624 and Clinilabs at booth # 650. To schedule a private meeting with the Clinilabs and NewCardio teams, please contact Jeanine M. Estrada, Clinilabs' Director of Business Development, at 646.438.4431. About Clinilabs, Inc. Clinilabs is a contract research organization (CRO) that provides clinical drug development services to industry. The Company offers teams, facilities, processes, and technology solutions for the conduct of early phase and specialty studies, and also operates a core data center that processes biomedical device data from global, multicenter projects. Since 2001, the company has worked with nine of the top 20 pharma companies in the world on trials conducted in 33 countries to support nine successful new drug applications. For more information, visit www.clinilabs.com. About NewCardio, Inc. NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's three-dimensional ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com. Forward-Looking Statements This press release contains forward-looking statements regarding NewCardio. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward- looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements. To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0 Investor Contacts: Clinilabs, Inc. Ron Falcone, Controller (646) 215-6407 rfalcone@clinilabs.com NewCardio Hayden IR Jeff Stanlis, Partner (602) 476-1821 jeff@haydenir.com SOURCE NewCardio, Inc.